Still, physicians so far are being careful with GLP-1s in oncology, particularly with pancreatic cancer patients or those ...

Rhonda Pacheco, who oversaw Zepbound’s launch, will run Takeda’s U.S. business. Elsewhere, early data suggested Maze might have a “best-in-class” rare disease drug and Arrowhead challenged Ionis in ...

Modern obesity trials are inherently complex, but the momentum behind these therapeutics has never been greater. With over ...

One analysts called the Phase 2 study results a “best-case scenario” for a drug Rapport is developing to treat focal onset ...

An HHS spokesperson confirmed Prasad's reappointment as chief medical and scientific officer, one month after his surprising ...

The agency says it’s open to offering speedy approval pathways for new pain medications that can fight the ongoing opioid ...

Capsida is investigating the root cause of the death, which occurred in the first patient treated in a trial of the company’s ...

LB Pharmaceuticals, which has a schizophrenia medicine headed for late-stage testing, broke one of the longest droughts for ...

The drugmaker’s new CEO said the moves will help the company be more agile as it deals with competition in the obesity market ...

J&J executives have said they expect the therapy, Inlexzo, to become a future blockbuster and generate sales that ...

The venture arms of Merck KGaA and Novartis are among the investors involved in raising $67 million for NRG Therapeutics, ...

The companies said their updated shot spurred an increase in neutralizing antibodies against currently circulating strains, ...